Uni-Bio Science Group is committed
to becoming a globally leading
biopharmaceutical company

Board of Directors

• 

  Kingsley Leung

  Chairman

  

  • Chartered Financial Analyst (CFA), Member of Hong Kong Society of Financial Analysts (HKSFA)

  • Vice Chairman of First Sub-group (Chemical & Pharmaceutical), The Federation of Hong Kong Industries

  • Tsinghua University & INSEAD, EMBA

  • University of Oxford, M.Sc. in Pharmacology

  • Imperial College London, B.Sc. in Biochemistry (Honours)

  • Over 15 years of experience in life sciences and finance, with unique insights and forward-looking perspectives in biotechnology and financial investment.

  • Serves as Chairman of three leading biotechnology companies. Throughout his decade-long career, he has worked with major international financial institutions and mid-sized biotech enterprises, developing a comprehensive and effective management approach. Successfully led multiple M&A and fundraising initiatives, including a capital raising project exceeding USD 60 million and eight acquisition collaborations with partners such as Jiangsu Hansoh, Bristol Myers Squibb, and CSL.

  • Global Outstanding Young Leader by Asiaweek

  • Outstanding Entrepreneur Award by Capital Magazine

  • Hong Kong Young Industrialist Award 2020

  • Gen.T China Social Impact Award & Rising Pioneer 2021

  • Innovative Entrepreneur Award (Greater Bay Area+ Award) 2022

  • EY Entrepreneur of the Year 2023

• 

  Dawei Chen

  Vice Chairman

  

  • Peking University, Finance EMBA

  • National University of Singapore, MBA

  • Over 20 years of experience in corporate management, capital markets, and mergers & acquisitions. Has founded and invested in multiple enterprises, with extensive experience in domestic and international capital market operations.

  • Previously served as Chairman, CEO, Executive Director, and Vice Chairman at China Everbright Water Limited. Currently holds the position of Executive Partner at a Chinese equity investment fund and Chairman of a Singapore-based capital management company.

• 

  Frank Zhao

  CEO

  

  • University of Hartford, M.S. in Accounting

  • Peking University, B.A. in World Economics

  • U.S. Certified Public Accountant & Fellow Member of the American Institute of CPAs

  • Over 20 years of experience in listed companies and renowned accounting firms, having served as CFO for multiple listed enterprises and emerging innovative companies. Possesses extensive expertise in finance and management, with a proven track record in facilitating M&A transactions and business spin-offs for listed entities.

  • Previously provided services to several pharmaceutical companies, including KingMed Diagnostics Group and Simcere Pharmaceutical Group (listed in the U.S.), demonstrating deep insight into the pharmaceutical industry.

  • Previously held Financial Controller positions at multiple listed companies and emerging innovative firms

• 

  Jacky Wen

  COO

  

  • South China University of Technology, Ph.D. in Fermentation Engineering

  • With over 30 years of dedication to the biopharmaceutical field, he possesses deep expertise in biotechnology, GMP/GLP systems development, new drug R&D, and clinical project management. Having contributed to Uni-Bio Science Group for more than two decades, he spearheaded the planning and construction of a biotechnology pilot testing base in Southwest China, driving the industrialization of scientific research through exceptional leadership.

  • His professional contributions have been recognized with the Chinese Academy of Sciences Award for Scientific and Technological Progress, and he holds multiple core technology patents, continuously fueling the Group's innovation with scientific momentum.

• 

  Tony Yau

  Non-Executive
  Director

  

  • The Hong Kong Polytechnic University, B.Acc. in Accounting, First Class Honours

  • Hong Kong Institute of Certified Public Accountants Certified Public Accountant

  • Over 20 years of experience in capital markets and investment banking, with extensive advisory work on major listing projects and M&A transactions for leading enterprises.

  • Currently serves as Chief Executive Officer and Director of Fuller International Holdings Limited and Heung Kong Financial Group Limited. Previously held the position of Managing Director at Deutsche Bank, where for over 11 years led origination and execution of projects in the Asian consumer sector.Prior to May 2006, served as Vice President of the Investment Banking Division at BNP Paribas Capital (Asia Pacific) Limited for seven years.

• 

  Qing Zhang

  Non-Executive
  Director

  

  • Columbia Business School, M.B.A.

  • Peking Union Medical College, Tsinghua University, M.D.

  • Since 2020, has served as Partner at a U.S.-based equity fund, focusing on venture investments and company incubation in biotechnology and healthcare.

  • In the venture capital industry, she specializes in pharmaceuticals, digital health, and deep tech sectors. Has overseen and contributed to over 30 projects, including three companies listed on Nasdaq.

  • Previously served as a Resident Physician at Singapore General Hospital, accumulating extensive clinical experience. Holds a Medical Doctor degree from Tsinghua University Peking Union Medical College, and completed NGS-based oncology drug development training at Dana-Farber Cancer Institute/Broad Institute.

  • Serves as Mentor and Advisor to the California Life Sciences Association and holds an executive committee position with the Chinese Biopharmaceutical Association (CBA) North America Chapter.

• 

  Paul Chow

  Independent
  Non-Executive
  Director

  

  • Heriot-Watt University, MBA

  • Member of Hong Kong Institute of Certified Public Accountants

  • Member of Association of Chartered Certified Accountants

  • Member of Hong Kong Tax Association

  • Certified Tax Advisor

  • Over 26 years of extensive expertise in financial management, auditing, and tax strategy within professional accounting firms.

• 

  Qimin Ren

  Independent
  Non-Executive
  Director

  

  • Anhui University, M.A. in Economics

  • Possesses over 24 years of management experience. Previously served as Deputy Secretary-General and Executive Council Member of the China International Friendship Liaison Association, primarily responsible for matters related to the Chinese government, and arranged meetings for international government agencies, political parties, other business organizations, and senior levels of the Chinese government. Has held director and senior management positions in several companies. Served as Senior Advisor at the Beijing office of CIGNA Corporation, with primary responsibility for government relations affairs. Prior to this, Mr. Ren also held the position of General Manager of Gallup (China) Consulting Co., Ltd.

  • Currently serves as Executive Director of Carta Group Limited, a firm specializing in international public relations and government affairs advisory.

• 

  Qingshan Ma

  Independent
  Non-Executive
  Director

  

  • Peking University, B.A. in Finance & E-commerce

  • Chartered Financial Analyst (CFA)

  • Tsinghua University - INSEAD EMBA

  • Over 16 years of management consulting and advisory experience, having provided management consulting services to 15 Fortune 500 companies as well as multiple listed and high-growth enterprises.

  • Held the position of Consulting Director at both KPMG Advisory (China) and Accenture (China), Possessing extensive hands-on experience in data management, corporate performance management, business process optimization, and digital transformation.